Arkolith/Insider Trading/APRE/Form 4

Gilad Oren

President/CEO, DirectorAprea Therapeutics, Inc. (APRE) · full profile →Form 4 · filed Oct 15, 2024
Net Buying
Open-Market Buys
$3K
Open-Market Sells
$0
Net Open-Market Flow
$3K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 14, 2024Buy(P)1K$2.59$3K333K
Oct 10, 2024Buy(P)150$2.54$381332K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-108375) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML